Results 111 to 120 of about 1,140,114 (148)

Engineered bacterial therapeutics from synthetic biology to clinical translation: A multi-database scientometric analysis, 2000-2026. [PDF]

Hum Vaccin Immunother
Zhou H, He J, Chen J, Ge S, Yu P, Zhang W.   +5 more
europepmc   +1 more source

Special Issue "New Insights into Bioactive Peptides: Design, Synthesis, Structure-Activity Relationship (2nd Edition)". [PDF]

Int J Mol Sci
Mercurio FA, Leone M.
europepmc   +1 more source

Current landscape of RNA chemistry and delivery in cancer immunotherapy. [PDF]

RSC Chem Biol
Tobias H, Porter S, Marcelo I, Koons A, Spina SC, Culkins C, Kimmel BR.   +6 more
europepmc   +1 more source

A Ten-Year Trend of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> From United States Medical Centers: Results From the INFORM Surveillance Program (2015-2024). [PDF]

Open Forum Infect Dis
Sader HS, Mendes RE, Lock J, Papp-Wallace KM, Castanheira M.   +4 more
europepmc   +1 more source

Engineering microRNAs as multimodal cancer therapeutics. [PDF]

Mol Ther Nucleic Acids
Kang R, Tang D.
europepmc   +1 more source

DNL343 and Disease Progression in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

JAMA Netw Open
Paganoni S, Chibnik LB, Quintana M, Macklin EA, Detry MA, Vestrucci M, Paulon G, McGlothlin A, Wang J, Walk D, Elman L, Chase M, Heyd L, Harkey B, Sherman AV, Shefner J, Berry JD, Scirocco E, Giacomelli E, Yu H, Kittle G, Hall M, Ho D, Jawdat O, Ladha S, Locatelli E, Rivner M, Felice K, Katz J, Ajroud-Driss S, Fee D, Miller T, Rosow L, Quick A, Heitzman D, Foster LA, Maragakis NJ, Goutman SA, Rosenfeld J, Benatar M, Swenson A, Connors RD, Shroff S, Bedlack R, McIlduff CE, Chen IA, Fernandes JAM, Walsh A, Peltier A, Ilieva H, Diaz F, Kushlaf H, Beydoun SR, Myers B, Arcila-Londono X, Heiman-Patterson T, Elliott M, Whitesell J, Al-Lahham T, Elliott M, Olney N, Baer M, Jackson C, Young E, Caress J, Weiss MD, Kuenzler R, Nayar S, Kasarskis EJ, Simmons Z, Gibson S, Owegi MA, Goyal NA, Wymer JP, Gwathmey KG, Erickson A, Gursoy N, Alameda G, Bodkin C, Wu A, Martinez-Thompson J, Twydell PT, Andrews J, Bayat E, Rezania K, Usman U, McCluskey L, Kovvuru S, Jennings D, Garza-Meilandt A, Maciuca R, Cohen IV, Tamuly D, Eren E, Cudkowicz ME, Babu S, HEALEY ALS Platform Trial Study Group.   +96 more
europepmc   +1 more source

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. [PDF]

Cancer
Mian H, Faisal MS, Chen T, Brazauskas R, Oloyede T, Ahmed N, Afrough A, Anderson LD, Banerjee R, Berdeja J, Bidikian A, Devos J, Dhakal B, Dias A, Dima D, Efebera YA, Gowda L, Hansen DK, Hashmi H, Landau HJ, Lekakis L, Mirza AS, Narra R, Patel K, Rosko AE, Schroeder M, Sidana S, Usmani S, Pasquini MC, Nishihori T, Akhtar OS, Mohan M.   +31 more
europepmc   +1 more source

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial. [PDF]

J Clin Oncol
Srour SA, Chahoud J, Drakaki A, Curti BD, Gibney GT, Tang L, Jiang Y, Charmsaz S, Robbins PB, McLeroy J, Severyn CJ, Le Gall JB, Roberts ZJ, Tannir NM, Pal S, Kotecha RR.   +15 more
europepmc   +1 more source

A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma. [PDF]

Clin Cancer Res
Chon HJ, Heo J, Kim DY, Lim HY, Macarulla T, Gomez Martín C, Moreno V, Reig M, Ryu MH, Yoon JH, Baumann P, Bhoi S, Jensen M, Tunblad K, Wallberg H, Öberg F, Evans TRJ.   +16 more
europepmc   +1 more source